AMW GmbH

Poland

All drugs from this manufacturer

  • LIBREXA

    The medicine is used in men for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and as adjuvant therapy during and after radiotherapy for locally advanced prostate cancer.

    Dosage form: implant in ampoule-syringe

    Active substance Dosage
    leuprorelin acetate 10.72 mg
    leuprorelin 12.1 mg

    ATC: L02AE02